Pengyang Yiliao Raises Series B+ Funds for Cardiovascular Product Development
Pengyang Yiliao, a Beijing-based developer and manufacturer of cardiovascular technology, has reportedly raised “tens of...
Company
Zhejiang Medicine’s ARX788 Shows Positive Results in Breast Cancer Study
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has announced positive results from a Phase II/III...
Glowe Raises Series A+ Funding to Expand AIGC in Mental Health
Glowe, an online psychological consultation platform based in Guangdong, has reportedly raised “tens of millions”...
Geneus Tech Secures Funding for Gseq500 Gene Sequencer Production
Geneus Tech, a Shenzhen-based developer and manufacturer of gene sequencers, has reportedly raised an undisclosed...
Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development
China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...
CanSino Biologics’ Inhalable COVID-19 Vaccine Gets EUA in Indonesia
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...
BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4...
Viatris Reports Q4 2022 Results, Highlights China Growth
US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The...
China Performs First AB-BNCT Procedures Outside Japan
The first accelerator-based boron neutron capture therapy (AB-BNCT) procedures have been performed in China by...
HutchMed Reports 2022 Financial Results with Revenue Growth
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has released its financial results for the...
3SBio’s Nalfurafine Tablets Accepted for Review by NMPA for Chronic Liver Disease
China-based 3SBio Inc. (HKG: 1530) has announced that a clinical trial filing for its nalfurafine...
3SBio Terminates Distribution Agreement with AstraZeneca for Byetta
China-based 3SBio Inc. (HKG: 1530) has announced the termination of a distribution agreement with UK...
JW Therapeutics Initiates Clinical Study for JWATM214 in Advanced Hepatocellular Carcinoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
FibroGen Reports Q4 2022 Financial Results with Revenue Growth
US-based FibroGen Inc. (FGEN) has released its Q4 2022 financial results. The company reported global...
Bayer Reports 2022 Sales Growth, Highlights New Drug Performances
Germany-based Bayer (ETR: BAYN) released its 2022 annual report this week, revealing a global sales...
Topchoice Medical to Acquire 19% Stake in Heren Health for $72.2M
China-based Topchoice Medical Investment Corp., (SHA: 600763) a leading medical service group, is set to...
Eluminex Biosciences Closes $40M Series B for Ophthalmic Innovations
China-based ophthalmic biotech Eluminex Biosciences (Suzhou) Ltd has announced the closure of a Series B...
RinuaGene Raises $14.4M in Pre-Series A+ for mRNA Drug Development
RinuaGene, an mRNA-based drug developer based in Suzhou, has reportedly raised close to RMB 100...
Junshi Biosciences Reports 2022 Preliminary Earnings with Revenue Decline
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has released its 2022 preliminary earnings estimate, indicating...
Chipscreen Biosciences Licenses First-in-Class BsAb YH008 from Eucure
China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with...